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Abstract
Adjuvants have been considered for a long time to be an accessory and empirical component of vaccine formulations. However, 
accumulating evidence of their crucial role in initiating and directing the immune response has increased our awareness of the 
importance of adjuvant research in the past decade. Nevertheless, the importance of adjuvants still is not fully realized by many 
researchers working in the vaccine field, who are involved mostly in the search for better target antigens. The choice of a proper 
adjuvant can be determinant for obtaining the best results for a given vaccine candidate, but it is restricted due to intellectual 
property and know-how issues. Consequently, in most cases the selected adjuvant continues to be the aluminum salt, which 
has a record of safety, but predominantly constitutes a delivery system (DS). Ideally, new strategies should combine immune 
potentiators (IP) and DS by mixing both compounds or by obtaining structures that contain both IP and DS. In addition, the term 
immune polarizer has been introduced as an essential concept in the vaccine design strategies. Here, we review the theme, 
with emphasis on the discussion of the few licensed new adjuvants, the need for safe mucosal adjuvants and the adjuvant/im-
munopotentiating activity of conjugation. A summary of toxicology and regulatory issues will also be discussed, and the Finlay 
Adjuvant Platform is briefly summarized. 
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Introduction
Adjuvants are molecules, compounds or macromolecular complexes that boost the potency and longevity of the 
specific immune response to antigens (1). Most adjuvant research has been an empirical process until recently, when 
an increased understanding of the mechanisms of immune response induction and the essential bridging of innate and 
adaptive immune responses has paved the way to a more rational adjuvant design. These breakthrough advances 
involve a deeper knowledge of how the innate immune system acts to recognize pathogens and damage-associated 
signals and how this recognition by different receptors may ultimately influence the potency and polarization of the im-
mune responses.
A functional classification of adjuvants was elaborated by Schijns (2), categorizing these molecules as facilitators of 
signal 1 (delivery of antigen) or signal 2 (i.e., appropriate immunostimulation; costimulation). Later, Valenti and O’Hagan 
(3) divided adjuvants into immune potentiators (IP) and delivery systems (DS). An additional category of adjuvants may 
be recognized as immune polarizing (IPz) components that are capable of shifting the immune response in the desired 
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direction required for protection (4), also referred to as signal 3 in the classification of Schijns (2). This last concept is 
extremely important: as long as the required protective response is known, it is possible to rationally select the appropri-
ate adjuvant to facilitate it. 
In other words, vaccine adjuvants are capable of enhancing, sustaining and directing the immunogenicity of antigens, 
thereby effectively modulating appropriate immune responses, reducing the amount of antigen and/or number of required 
immunizations, and improving the efficacy of vaccines, which is of increased relevance for vaccination strategies aimed 
at newborns, elderly, or immune-compromised individuals (5). It is important to stress, however, that they need to cause 
minimal toxicity and avoid long-lasting immune effects on their own in order to be translated to clinical practice.
One major current question in the vaccinology field is whether adjuvants are additional or essential components of 
vaccine formulations. For a long time, only live or attenuated organisms and vaccines containing aluminum salts (alum) 
have proven successful. However, vaccine history has traditionally focused on the identification of particular antigens 
and more restrictedly single epitopes to induce protection. Research on vaccine adjuvants has so far received little at-
tention as an independent scientific discipline from most of the main research-funding agencies and policy makers (6), 
although some pharmaceutical companies have made adjuvant research a priority. Today we are in the golden age of 
adjuvant research as a result of two factors. First, vaccinology per se (either prophylactic or therapeutic) is in its golden 
age, and second, our knowledge of immunology has dramatically improved, especially regarding the recently appreci-
ated role of innate immunity as an essential part of the immune system, indispensable to bridge towards and amplify 
adaptive immunity. In this review, we aim to discuss the role of adjuvants in vaccine formulations and how they are being 
increasingly explored to rationally design more efficient vaccines.
Learning from current vaccines
There are currently 90 registered prophylactic vaccines produced by different companies against 31 bacterial or 
viral pathogens, but no vaccines against protozoan or helminths. This survey does not include: 1) vaccines against the 
same disease applied by different routes (like polio); 2) vaccines that cover different serogroups (like serogroup B and 
C of VA-MENGOC-BC™, conjugated A, C, Y, and W135, and pneumococcal serogroups), and 3) mixed and combined 
vaccines. Interestingly, there are several vaccines against the same diseases: the differences in formulations are the 
results of the search for intellectual properties.
Live attenuated and inactivated plus adjuvant (non-alum salt) vaccines
Table 1 lists the live-attenuated and inactivated current vaccines, which are presented together because they are 
considered to be non-adjuvanted, but contain several immunostimulants with adjuvant behavior, which are intrinsic to 
the organisms they are made of. Sixteen vaccines contain most attributes of live pathogens and induce a potent/efficient 
immune response and protection, being considered as the most efficient vaccines developed so far. Consequently, the 
poly-antigens and -adjuvants present in these vaccines allow the induction of potent immune responses without the re-
quirement of additional adjuvants. Nevertheless, some of them, like whole cell pertussis, hepatitis A, and split flu virus, 
are also formulated with other adjuvants.
Natural immunostimulants present in live-attenuated or inactivated vaccines exert adjuvant activity or function as 
antigens. Components with adjuvant properties are usually more than one and are expressed in multimeric form. They 
depend on the microorganism from which they are coming, i.e., Gram-negative bacteria contain lipopolysaccharide (LPS), 
porins, flagellin, and bacterial DNA as the main pathogen-associated molecular pattern (PAMP), but viruses contain 
mainly dsRNA or ssRNA as main PAMP (reviewed in Ref. 7). Antigens are often also multimeric, and with the aid of the 
associated adjuvants’ activity guarantee a broader spectrum of immune response, thereby resulting in a more efficient 
avoidance of pathogen-escape mechanisms. 
The live-attenuated pathogens naturally contain several IP, DS, and IPz agents that induce strong stimulation of the 
innate immune response and favor adaptive immune responses with the desired pattern. In addition, the in vivo persis-
tence and multiplication of live organisms elicits prolonged immune stimulation, often after a single dose. 
However, due to their strong potency, these vaccines induce important adverse reactions, which can range from simple 
headache to encephalitis (mumps-measles-rubella), intussusception (rotavirus), vaccine-associated diseases (polio) and 
even death (smallpox) (8). The inactivation or attenuation processes in general tend to decrease the proportion of the 
most harmful components reducing the reactogenicity, but this decrease is not enough to eliminate it completely. Hence, 
it is very unlikely that new vaccines in this format would be approved today by regulatory bodies (9). 
Note that three live vaccines are oral (two against rotavirus, produced by different companies), and only one is nasal. 
Two other vaccines consist of inactivated organisms and contain several attributes of the source pathogens, but fail to 
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multiply. Therefore, they might become less effective than live-attenuated vaccines, but are also less reactogenic. Typical 
reactions range from nausea to anaphylactic reactions and neurological complications (6).
Conjugated vaccines
Conjugation has been a great contribution of chemistry to the field of vaccinology. This technique has been used to 
help induce a long-lived, thymus-dependent (TD) response against thymus-independent (TI) antigens such as polysac-
charides. A list of current conjugated vaccines is presented in Table 2.
Antigens can be classified as TD (most proteins) or TI. The TI responses are divided into types 1 and 2. The TI-1 
inducing LPS present lymphocyte-B mitogenic activity at high doses, and a specific response at low doses. They stimulate 
immature and mature B cells in newborn, and IgM antibodies in CBA/N (xid) mice. In contrast, the TI-2 like polysaccharides 
have repetitive epitopes, are resistant to degradation and activate the complement system. They only stimulate mature 
B cells, and this stimulation does not occur in newborn or xid mice (10). They induce IgM and IgG antibody specific 
responses (of the IgG3 subclass in mice, and IgG2 in humans) (11,12). T cell-independent antibody responses do not 
induce memory; consequently, they induce short-lived protection. 
In vaccinology, the covalent conjugation of a TI-2 polysaccharide to a carrier (which is, most of the time, of protein 
origin) transforms it in a TD antigen. The carrier adds mainly T helper (Th) epitopes, solving most problems associated 
with TI-2 antigens for children under 2 years of age (13). Neonates can mount effective antigen-specific T-cell responses, 
even though CD4 T-cell responses are often slower to develop, less readily sustained and in most cases more easily 
biased towards a T helper 2 (Th2) type of response, most probably because of the decreased efficiency of neonatal 
dendritic cells (DCs) to establish Th1 CD4 T-cell responses (14). Neonates and infants may require multiple immuniza-
tions to achieve or sustain titers comparable to those in older individuals (15).
Conjugated vaccines provide T cell help by using a carrierpreferably covalently linked to saccharides, thus we con-
sider this to be a form of adjuvation. The most prevalent carriers include: tetanus toxoid, CRM197 (nontoxic Diphtheria 
toxin mutant), and outer membrane proteins from Neisseria meningitidis serogroup B. One forthcoming problem is the 
repetitive use (including that all are vaccine antigens) of the few currently used carriers that might become immune 
dominant, resulting in vaccine failure.
Alum-based vaccines
Formulations with alum have a long record of safety, mainly because alum entraps the antigens in depot areas and 
is slowly liberated (a few hours may be sufficient) or taken up by phagocytosis. Table 3 lists current vaccines that employ 
alum as an adjuvant. There are several caveats related to the use of alum: alum includes three different compounds (alu-
minum hydroxide, aluminum hydroxyphosphate, and aluminum hydroxy-phosphate-sulfate), it may include self-inactivated 
antigens with inherent adjuvant behavior, and finally, other adjuvants have been included in the alum formulation. It is 
important to note that the accidental freezing of alum-containing vaccines destroys the formulation and impairs the ef-
ficacy of the vaccine. This is estimated to occur in up to 70% of available vaccines in low income countries (16). Finally, 
alum can induce granulomas at the injection site, a concern for vaccines requiring frequent boosts (17).
The mechanisms underlying the adjuvant properties of alum are still not completely understood. Alum induces par-
ticulate and depot formation, inflammation, recruitment of antigen-presenting cells, increased major histocompatibility 
complex (MHC) class II expression and antigen presentation, T-cell activation and differentiation, and boosts the humoral 
immunity by providing Th2 cell help to follicular B cells (18). This involves an increase in uric acid levels (19) and nucle-
otide oligomerization domain (NOD)-like receptor family, NALP3-dependent caspase-1 activation and interleukin (IL)-1β 
secretion (20). Interestingly, alum does not trigger classical DC maturation in vitro (21). 
Alum activity has been associated with the secretion of uric acid (19). This concept is strongly challenged by earlier 
data showing that uric acid crystals augment cytotoxic T lymphocyte (CTL) responses to co-injected antigen, which, by 
contrast, was not observed for alum in the same animal experiments (22). Hence, uric acid polarizes the immune re-
sponse towards a CTL reaction, which is Th1 associated, while a Th2-type response is the hallmark of alum adjuvanted 
vaccines. In fact, the lack of proper CTL priming by alum may represent its major deficiency as a vaccine adjuvant. 
Nevertheless, a recent report has demonstrated the capacity of alum to help in the generation of antigen-specific cyto-
toxic/interferon-γ producing effector-memory CD8+ T cells, but this has occurred only in the presence of an additional 
adjuvant, monophosphoryl lipid A (MPL) (23).
Alum has been shown to be able to activate the NALP3 inflammasome in human peripheral blood cells (24) and in 
primary peritoneal macrophages of mice (20). However, such activation is dependent on cell priming with LPS. Remark-
ably, in NALP3-deficient mice, only a partial reduction of alum-induced antigen-specific antibody formation was observed 
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using ovalbumin (OVA) or human serum albumin as antigens (20,24). NALP3-deficient mice are able to mount normal 
antibody responses when immunized with antigen in alum adjuvant (25). Furthermore, of particular importance is a recent 
study demonstrating that mice lacking myeloid differentiation primary-response gene 88 (MyD88), and therefore unable 
to respond to Toll-like receptor (TLR) signals or to IL-1β and IL-18 (26), are still capable of generating normal antibody 
responses when stimulated by repository vaccine adjuvants including aluminum hydroxide and Freund’s incomplete 
and complete adjuvant (27). Also humoral immune responses such as OVA-specific immunoglobulin (Ig)G1 and IgE 
production (the hallmark of alum’s adjuvant effects) remained unaffected in IL-18-deficient mice (28). Taken together, 
these data do not support the recently proposed NALP3 pathway (20), nor the uric acid concept (19) for alum adjuvant 
activity. In addition, there is no evidence for IL-18 or IL-1β dependence. 
Recent reports have shown possible NALP3-independent mechanisms that may account for the adjuvant behavior 
of alum. Alum crystals have been shown to be capable of interacting with lipids in the plasma membrane DCs, including 
cholesterol and sphingomyelin, inducing lipid sorting that leads to cell activation through a Syk- and PI3K-dependent 
mechanism. In this system, alum-treated DCs up-regulated intercellular adhesion molecule-1 (ICAM-1) increasing their 
interaction with CD4+ T lymphocytes (29). On the other hand, the moderate cytotoxicity of alum may lead to a limited but 
functionally important release of molecules that act as damage-associated molecular patterns (DAMPs), among them 
host DNA, which has the property of stimulating humoral responses through the Irf3 pathway (30). 
Alum is not always satisfactory as an adjuvant (31,32). New potent adjuvants are particularly required to: 1) induce 
immunity with long-term protection and immunological memory; 2) overcome weak immunity during the neonatal pe-
riod, during immune-suppression or immune-senescence; 3) overcome the escape mechanism of invaders or tumors; 
4) induce a broader immune response against serogroups, serotypes, immunotypes, or other subgroups of the same 
species; 5) stimulate strong T-cell responses, including CTL, and 6) reduce the schedule of immunization (fewer doses, 
less antigen concentration).
Non-adjuvanted vaccines
There are only few non-adjuvanted vaccines (Table 2). These include polysaccharide-based vaccines, which are not 
suitable for infants less than 2 years of age, when some of these diseases are important. 
Newly licensed adjuvants
So far, only alum and ASO4 adjuvants are licensed as part of human vaccines in the US. Other proposed adjuvants 
are licensed mainly in Europe. Vaccines using newly licensed adjuvants are listed in Table 4. MPL was the first IP ca-
pable of activating T-cell effector responses to be used in a licensed vaccine. MPL is a nontoxic derivative of the LPS 
of Salmonella minnesota (33). On the other hand, the Neisseria meningitidis B proteoliposome adjuvant AFPL1, which 
contains inserted natural LPS, has been used in the meningococcal BC vaccine (34), and is the most extensively used 
LPS-derived adjuvant, with more than 55 million doses given so far (27 million of vaccinees) (35). MPL alone is only used 
in allergy immunotherapy (36) but in combination with other adjuvants (alum, QS21, O/W, RC529) it is used in several 
vaccines. MF59TM consists of an oil (squalene)-in-water nano-emulsion composed of <250 nm droplets (37), and is used 
in Europe against influenza (38). AS03 is an adjuvant system containing a 10% oil-in-water emulsion-based adjuvant, 
and was approved for use in influenza (39). AS04 is an aqueous formulation of MPL and alum (40). Virosomes are lipo-
somes that have proteins or lipids from the envelope of a virus. These could be viral-like particles (VLP) or reconstituted 
virosomes (IRIV). The VLPs are self-assembling nano-particles composed of one or more viral proteins and viral lipids. 
The IRIV is a virosome constituted by phospholipids, influenza hemagglutinin, and a selected target antigen (41). It is 
expected that within the next 5-year period, in addition to the TLR4 agonists MPL and AFPL1 (which is also an agonist 
of TLR2 and TLR9), other TLR-based adjuvants will become components of vaccines approved for human use (6).
Mucosal adjuvanted vaccines
Assuming that the protection induced by recovery from natural infection is in general better than that induced by vac-
cination, and given that the invasion or establishment of the vast majority of pathogens occurs in the mucosal tissues, it 
is reasonable to consider that vaccines may work better when applied via mucosal routes. More than 90% of infectious 
agents enter or establish themselves in the 400 m2 of mucosa where millions of commensal species live. However, the 
majority of existing vaccines (both prophylactic and therapeutic) are given via the parenteral route, which fails to induce 
strong mucosal immune responses. 
Presently, vaccine researchers, vaccine companies, and founder agencies emphasize that future vaccines need to 
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be developed for alternative routes of immunization, particularly the important but less exploited mucosal route. Mucosal 
immunization offers a number of potential advantages over the parenteral vaccination, including reduced risk of reac-
togenicity/toxicity and of transmission of infectious agents (for example through contaminated needles carrying human 
immune-deficiency and hepatitis B viruses), as well as enhanced patient compliance due to ease of administration and 
minor invasiveness. The mucosal route also allows the induction of both mucosal and systemic immune responses, a 
feature that other routes do not exhibit. 
The two main mechanisms of immune protection at mucosal sites are the production of secretory IgA (SIgA) and 
the induction of CTL. SIgA is the main immune-specific element involved in mucosal protection. Nearly 80% of all im-
munocytes are in the mucosa and 70% of them are CD8+ T cells. However, our understanding of mucosal immunity and 
of how to develop mucosal vaccines remains largely incomplete (6). 
Even though IgA is produced abundantly (~3 g per day) there are important questions concerning this antibody class. 
The first is how to induce preferably antibodies of the IgA2 subclass, which are more resistant to protease digestion pro-
moted by several nasopharyngeal bacterial infections. The second is how the organism can produce this huge amount 
of IgA in an environment that is rich in regulatory T cells. The third question is how the balance between specific and 
nonspecific or cross-reactogenic IgA is established. 
The induction of potent mucosal immunity by mucosal administration of protein antigens has often proven to be dif-
ficult, and the recovery and functional testing of antibodies or T cells from mucosal sites are labor intensive and techni-
cally challenging (42). The mucosal route, particularly the oral one, is more often involved in the induction of tolerance, 
mainly to food (43). The epithelial mucosa is more fragile than other tissues, and needs to be protected from inflammation 
(reviewed in Ref. 44). Nevertheless, both probiotic (commensal) and dangerous microorganisms somehow elicit some 
kind of mucosal immune response. Commensal organisms (e.g., Bacteroides thetaiotaomicron) not only induce mucosal 
responses required to control them but also modulate many genes involved in the intestinal barrier function and in nutrient 
absorption (45). The ability to contain the microbiota in this region is dependent on pattern recognition receptors (PRRs), 
since a deficiency in TLR signaling results in the increased uptake of bacteria and consequently of their recovery in the 
spleens of mice (46). The importance of NOD signaling in the mucosa has been well established (47). NOD2 deficiency 
results in the abnormal development and function of Peyer’s patches in mice (48), which become more susceptible to 
oral infection with Listeria monocytogenes (49). NOD1-deficient mice are also highly susceptible to infection with Heli-
cobacter pylori (50). Regulatory T cells in the intestine maintain immunological tolerance to self-antigens and have an 
important role in suppressing damaging inflammatory responses (48). However, DNA from commensal bacteria limits 
the induction of inducible regulatory T cells through TLR9 signaling (51).
The microbiota has an essential role in promoting the development of IgA-producing plasma cells and there is evi-
dence that this enhancing effect is driven by specific bacterial species (44). TLR5 has been demonstrated to promote 
IgA+ B-cell differentiation. A population of TLR5+CD11c+CD11b+ DCs in the small intestine promotes IgA+ cell differentia-
tion by a retinoic acid-dependent process (52). Mice deficient in activation-induced cytidine deaminase, which leads to 
a loss of IgA-producing plasma cells, exhibit expansion of anaerobic, particularly segmented filamentous bacteria in the 
small intestine (53). TLR agonists can act directly on B cells in the presence of transforming growth factor-beta (TGF-β) 
to promote IgA class switching in B cells (44). A population of tumor necrosis factor (TNF)/inducible nitric oxide synthase 
(iNOS)-producing DCs in the intestinal lamina propria produces nitric oxide and this leads to the induction of B cell-
activating factor of the TNF family (BAFF) and a proliferation-inducing ligand (APRIL), which promote activation-induced 
cytidine deaminase expression and IgA class switching (54). The development of TNF/iNOS-producing DCs requires TLR 
signaling, as the numbers of these cells in the lamina propria are reduced in MyD88-deficient and TLR2−\−TLR4−\−TLR9−\− 
mice (55). As IgA can have protective roles in immunity against pathogens, targeting cells including TNF/iNOS-producing 
DCs and TLR5-expressing DCs may have potential in vaccine development (56) and mucosal adjuvant discovery. 
Th17 cells are a subset of Th cells that are implicated in protection against a number of extracellular pathogens, 
including the enteric pathogen Citrobacter rodentium (57) and in autoimmune conditions (58). Th17 cells are highly 
enriched and constitutively present in the intestinal lamina propria (59). This requires microbiota, as the numbers of 
Th17 cells are reduced in germ-free mice (60). The enteric pathogens Lysteria monocytogenes and Shigella flexneri 
have been found to signal to Th17 cells (61). Remarkably, however, the development of Th17 cells in the lamina propria 
has been found to be independent of TLR signaling, as it was intact in MyD88/TIR-domain-containing adapter-inducing 
interferon-β (TRIF)-deficient mice. There were lower concentrations of luminal ATP and Th17 cells in germ-free mice, 
implicating the microbiota in both processes. Thus, both MyD88-dependent and -independent mechanisms for Th17 cell 
development probably exist. NLRP3 may be a mediator of commensal bacteria-induced Th17 responses in the intestine 
(56). In addition, γδT cells, which are abundant in the intestinal epithelium (62), respond to stimulation with IL-1 and IL-
23 by secreting IL-17, and act to amplify Th17 cell responses (63).
A major limitation of the development of mucosal vaccines is the lack of a safe and nontoxic human mucosal adjuvant. 
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Most existing mucosal vaccines contain adjuvant (immunostimulant) from live-attenuated or inactivated microorganisms. 
Note that the strongest mucosal adjuvant for animals is the complete cholera toxin (CT). There are no added mucosal 
adjuvants in currently licensed vaccines.
 Mucosal adjuvants must abrogate the normal tolerance induced by mucosal encounter, protect the antigens against 
expulsion and degradation, thereby allowing epithelial transport, and direct polarization. Microparticles instead of nano-
particles seem to be more suitable for the mucosal routes (Pérez O, Lastre M, Romeu B, Cuello M, Cabrera O, Balboa 
J, unpublished results). 
The essence of formulation
Apart from the type of adjuvant that is selected, the influence of formulation is also underestimated by many vacci-
nologists. Adjuvants have limited or no efficacy unless properly formulated. Formulation (e.g., oil-in-water, particle size, 
charge, etc.) is essential not only for the stability and the immunogenicity of the adjuvanted vaccines, but also to reduce 
their reactogenicity and to enhance vaccine potency (22). Most of this information is not published and remains as the 
know-how of companies, but one good example is related to particle size. Nonoparticles are recommended for parenteral 
formulation but microparticles for mucosal formulations. Nevertheless, this dogma is not always correct. It depends also 
on the composition of the adjuvant. Using adjuvant Finlay cochleate 1 (AFCo1), a proteoliposome-derived cochleate of 
microparticle size, we induce not only mucosal but also parenteral immune responses (Lastre M, unpublished results). 
The vaccine formulation must favor the IPz desired for a given antigen, the route of immunization expected to obtain a 
safe, stable, biodegraded product and an inexpensive production method. Furthermore, the ideally formulated adjuvant 
will be well defined chemically and physically to facilitate quality control that will ensure reproducible manufacturing and 
activity (22). 
These are also the major concerns that affect the hurdle of translation from the preclinical stage vaccine to the clinical 
one, and it explains why most companies prefer alum, which is the most accepted and known adjuvant. Nevertheless, 
several companies recognize the need for new adjuvants and good formulations (64).
The particular case of AFPL1 and AFCo1 adjuvants, proteo-cochleates
These represent two of the Finlay adjuvant platforms or adjuvant family (AFPLx and AFCox). This platform is based 
on the following principles: they contain multiple IP (PAMPs) exhibiting synergistic activity, which make them a potent 
adjuvant. Proteo-cochleate (AFPL1-AFCo1) contains synergistic PAMPs like native LPS inserted in the lipid bilayer (this 
LPS is not free, which results in reduced toxicity), porins (Por A and B), and traces of bacterial DNA that contribute to 
IP activity. Consequently, it interacts with TLR4, TLR2, and TLR9, respectively (4,65); the delivery system is based on 
non-living lipid structures extracted from the outer membrane of microorganisms (66) and on inclusion of immune IPz 
to induce the desired quality of immune response, associated with protective immunity. AFPL1 is derived from outer 
membrane proteins (forming vesicles) from serogroup B N. meningitidis and is already used as the main component of 
meningococcal BC human vaccine, called VA-MENGOC-BC™ (40). It has been applied in more than 60 million doses 
in the world, mainly in Cuba and Latin America. It induces a preferential Th1 pattern of response characterized by IgG2a 
production in mice, and IgG1/3 production in humans, as well as increased IFN-γ, and no specific IgE or IL-4/5 (67). In 
addition, cross-priming presentation and in vivo CTL response are also induced (68); IP, DS, and IPz are in the same 
structure-forming particles (nano- or microparticles), but with similar components between each (AFPLx-AFCox) pair. 
Most adjuvant strategies are based on a combination of IP and DS. By contrast, our strategy is based on structures that 
contain all the adjuvant components together. This may explain why the Finlay Adjuvant Platform has exhibited high 
potency for several vaccines; the potential to be formulated with inserted or co-administered antigens/allergens (69); the 
capacity to induce persisting immune response or long-lasting memory (70); safety and maintained capacity of stimulation 
at extreme ages (old age and infants). VA-MENGOC-BC™ containing AFPL1 has been applied in more than 2 million 
doses to infants of 3 months of age, and AFCo1 proved to work safely in neonatal mice (71); the suitability for parenteral 
and mucosal routes (72); the possibility to increase coverage and compliance with the development of simultaneous 
vaccination strategies (STVS). STVS consists of the simultaneous use of a mucosal dose with a parenteral one, resulting 
in a systemic specific IgG response similar to two parenteral weekly spaced doses, and several weekly spaced mucosal 
doses (73); consistent production. AFPL1 has been produced for more than 20 years on the industrial scale under good 
manufacturing practice conditions at the Finlay Institute, and AFCo1 is currently at the stage of production development 
(74); proprietary products (75). 
This Finlay adjuvant platform is at the forefront of the development of new vaccines, particularly new mucosal vac-
cines. Two decades of experience working with this vaccine adjuvant platform have allowed us to expand its potential 
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use to vaccines against life-threatening human diseases as well as veterinary vaccines. Several AFPLx are in the stage 
of preclinical evaluation. Two AFCox, the AFCo1 and the AFCo2, have already been obtained (4). The potential use of 
AFCox derived from AFPLx for the mucosal route has recently completed the stage of experimental development.
Current major problems in adjuvant research
The first problem is that an adjuvant is not licensed in the absence of antigens. This is a consequence of the fact that 
adjuvant research is not viewed as an independent field in vaccinology. Therefore, each vaccine needs to go through all 
the phases of preclinical and clinical development whenever the adjuvant is changed, and the same adjuvant needs to 
be tested in each new formulation. Also, as mentioned above, the influence of the formulation is underestimated by many 
vaccinologists. Consequently, the evaluation of antigens as vaccine candidates has often been discontinued only because 
of a poor adjuvant selection or due to an unsuccessful formulation (21). To ensure that new and existing adjuvants will 
be available for use in vaccines and immunotherapy, the research and development protocol of adjuvant candidates 
should include checking for accessibility, cost of consumables and compliance with current and foreseeable regulatory 
issues. The development of candidate adjuvants should focus on establishing modular and transferable standard oper-
ating systems. Procedures and batch records for processing, production and fill-finishing, in addition to analytical tools, 
are essential. Procedures to evaluate the performance of the process and final product need to be established. At the 
same time, development should also attempt to remove problematic materials such as animal-derived components that 
might raise regulatory and comparability issues. Combining this view of raw material sourcing with attention to the cost 
of consumables should allow the development of sustainable adjuvant formulations that will have long product lifetimes 
without major changes in manufacturing and sourcing. Lastly, there are no human nontoxic mucosal adjuvants available, 
a problem that needs attention with high priority. Table 5 summarizes these major concerns.
Adjuvants and adverse effects of vaccination
Before licensure, vaccines are tested for safety and efficacy in preclinical tests performed in the laboratory, frequently 
with the use of animals, and in phase I clinical trials. Due to their experimental design (i.e., randomization, placebo-
control, blinding), inferences on the causal relationship of an adverse event with the vaccine in such trials are relatively 
straightforward. Unfortunately, while helpful in providing data on common acute vaccine reactions (e.g., fever, swelling), 
pre-licensure trials usually cannot provide data on rare reactions (e.g., occurring <1/1000 doses), reactions with delayed 
onset (e.g., ≥30 days after vaccinations), or reactions in specific subpopulations (e.g., infants are normally excluded from 
trials) (76). Post-licensure (also called post-marketing) evaluation of safety, after vaccines are administered to thousands 
or millions of persons, is therefore critical. Historically, such monitoring has relied on passive surveillance systems, like 
the Vaccine Adverse Event Reporting System, which may result in under-registration of rare adverse effects post vac-
cination. Therefore, immune epidemiological studies are needed to assess whether immunizations may involve risks 
for some susceptible individuals. Many serious adverse reactions to vaccines are a consequence of immune system 
stimulation, resulting in exacerbated inflammation, and, in some rare cases, autoimmune reactions. One well-known 
incident occurred in 1976, in the United States, when recipients of the ‘swine influenza’ vaccine were found to display an 
8-fold increased risk of developing Guillain-Barré syndrome when compared to non-vaccinees (77,78). Other examples of 
such adverse effects range from hepatitis B vaccine-associated multiple sclerosis (79) to infant immunization-associated 
type 1 diabetes mellitus (80). Some human vaccine withdrawals following serious adverse effects have occurred. In one 
example, the adjuvant labile enterotoxin B (LTB) subunit has been proven to have affinity for the central nervous system 
ganglioside GM1, a phenomenon that is probably responsible for the facial palsy seen when this molecule is administered 
nasally (81). It is obvious that several barriers must be overcome to meet the demands for new adjuvants. Unaccept-
able side effects and toxicity are still important barriers for most candidates, particularly for the development of pediatric 
vaccines. In addition, regulatory standards for adjuvant approval have improved substantially since the approval of alum 
(21). Many products have been proposed as vaccine adjuvants, but have been rejected because of safety concerns. 
Extensive research is therefore needed either to understand how to exploit current adjuvants safely or to explore novel 
products with better safety profiles.
Changes in the perception of adjuvant research
The field of vaccinology is currently in a golden era, including the field of adjuvant research. This can be measured 
by the increase in perception of the important role of adjuvants for improving the existing and novel vaccines (reviewed 
in Ref. 6). This perception is at the level not only of big pharmaceutical companies involved in human vaccines, like 
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GlaxoSmithKline and Novartis, but also at the level of small companies, like Finlay SA, of regulatory agencies, like the 
European Agency for the European Medicines Agency and the Cuban Center for the State Control of Medicines Quality, 
of non-profit organizations such as the Global Adjuvant Development Initiative and the Mucosal Vaccines for Poverty 
Related Diseases, and moreover, in the European Commission and World Health Organization.
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Table 1. Live attenuated and inactivated plus inherent adjuvant vaccines.
Adjuvant Vaccine Route Name Manufacturer
Live BCG id TICE BCG™ Organon Teknika 
Mycobax™ Sanofi Pasteur
Live Typhoid Ty21a Oral Vivotif™ Berna Biotech
Live Va sc Varivax™ Merck 
Live Zoster sc Zostavax™ Merck 
Live Rubella sc Meruvax™ II Merck 
Live Rotavirus Oral Rotarix™ GSK
RotaTeq™ Merck
Live Smallpox pc ACAM2000™ Acambis
Dryvax™ Wyeth 
Live Influenza in FluMist™ MedImmune 
Live Me sc Attenuvax™ Merck 
Live Mu sc Mumpsvax™ Merck 
Live Me/Mu sc M-M-Vax™ Merck (NA)
Live Me/Ru sc MoRu-Viraten™ Crucell
Live Me/Mu/Ru sc M-M-R™ II Merck 
Live Me/Mu/Ru/Va sc ProQuad™ Merck 
Live Yellow fever sc YF-Vax™ Sanofi Pasteur
Live Poliomyelitis Oral NTM Aventis-Pasteur, GSK, etc.
Inactivated Influenza im Afluria™ CSL Limited
FluLaval™ GSK
Fluarix™ GSK 
Fluvirin™ Novartis 
Fluzone™ Sanofi Pasteur
Influvac™ Solvay
Inactivated Rabies im Imovax™ Sanofi Pasteur
RabAvert™ Novartis
id = intradermal; sc = subcutaneous; pc = percutaneous; in = intranasal, im = in-
tramuscular; Va = varicella; Me = measles; Mu = mumps; Ru = rubella; NA = not 
available. 
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Table 2. Conjugated (including conjugation plus alum and conjugation plus built-in immunopotentiat-
ing components/antigens) and non-adjuvanted vaccines. 
Adjuvant Vaccine Route Name Manufacturer
 1 OMP NmB Hib im PedvaxHIB™ Merck
TT ActHIB™ Sanofi Pasteur 
TT Quimi-Hib™ Heberbiotec
 2 DT Poly A, C, Y, W135 im Menactra™ Sanofi Pasteur
 3 OMP NmB + Alum Hib+HB im Comvax™ Merck
 4 CRM197 + Alum Pneumococcal 7-valent im Prevnar™ Wyeth 
 5 CRM197 + Al4(OHPO4)3 Poly C im Meningitec™ Wyeth
CRM197 + Al(OH)3 Menjugate™ Novartis
TT + Al(OH)3 NeisVac-C™ Baxter
 6 TT + Alum + IPV DaPT+PV+Hib im Pentacel™ Sanofi Pasteur 
 7 TT + Alum + IPV DaPT+HB+PV+Hib im Infanrix hexa™ GSK 
 8 - Poly A, C im/sc Mengivac™ Sanofi Pasteur
Vax-MEN-AC™ Finlay
AC vax™ GSK
 9 - Poly A, C, W135, Y im Menomune™ Sanofi Pasteur 
ACWY vax™ GSK
10 - Typhoid Vi im/sc TYPHIM Vi™ Sanofi Pasteur
TyTherix™ GSK
vax-TyVi™ Finlay 
11 - Pnemococcus 23-valent im/sc Pneumovax™ Merck
OMP NmB = outer membrane protein from Neisseria meningitidis serogroup B; TT = Tetanus toxoid; 
DT = Diphtheria toxoid; alum = AL(OHPO4)SO, Al(OH)3, Al4(OHPO4)3; CRM197 = nontoxic Diphtheria 
toxin mutant; IPV = inactivated poliovirus; Hib = Haemophylus influenzae b; Poly A, C, Y, W135 = 
polysaccharides from Neisseria meningitidis serogroups A, C, Y, or W135, respectively; HB = hepatitis 
B; DaPT = Diphtheria, acellular Pertusis, Tetanus; PV = poliovirus; im = intramuscular; sc = subcu-
taneous.
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Table 3. Alum-based vaccines (alum, alum plus self-inactivated, and alum plus other adjuvants). 
Adjuvant Vaccine Route Name Manufacturer
 1 Alum Anthrax im Biothrax™ Emergent bioDefense 
 2 Alum Tetanus im vax-TET™ Finlay
NTM Sanofi Pasteur
 3 Alum DT, adult im TENIVACT Sanofi Pasteur
DECAVAC™ Sanofi Pasteur
VA-DIFTET™ Finlay
NTM Massachusetts PH Biologic Lab
 4 Alum dT, pediatric im VA-DIFTET™ Finlay
 5 Alum DaPT im Tripedia™ Sanofi Pasteur
Infanrix™ GSK 
Boostrix™ GSK 
DAPTACEL™ Sanofi Pasteur
Adacel™ Sanofi Pasteur
 8 Alum DTaP+HB+Hib im Quinvaxem™ Berna Biotech
 9 Alum, wP DT+wP+HB im Trivac-HB™ Heberbiotec
10 Alum, wP DTwP+HB+Hib im Heberpenta™ Heberbiotec
11 Alum, IPV Poliomyelitis im/sc Poliovax™ Sanofi Pasteur NA 
Ipol™ Sanofi Pasteur
12 Alum, wL Leptospira im Vax-SPIRAL™ Finlay
13 Alum, wP DTwP im NTM Finlay
14 Alum, IPV DaPT+PV im Kinrix™ GSK
15 Alum, IPV DaPT+HB+PV im Pediarix™ GSK 
16 Alum, IHA HA im Havrix™ GSK 
17 Alum, IHA HA+HB im VAQTA™ Merck
Twinrix™ GSK
18 Alum, IJE Japanese Encephalitis im Ixiaro™ Intercell Biomedical
19 Alum, IR Rabies im JE-Vax™ Res Fund Microbial Dis Osaka Univ 
20 Alum, AFPL1™ Meningococcus BC im VA-MENGOC-BC™ Finlay 
21 Alum, MPL HB im Fendrix™ GSK
22 Alum, MPL, VLP PV im Cervarix™ GSK
23 Alum, VLP HB im Heberbiovac-HB™ Heberbiotec 
Recombivax HB™ Merck
Engerix-B™ GSK
Hepavax-Gene™ Berna Biotech
Shanvac-B™ Shantha Biotech
24 Alum, VLP PV im Gardasil™ Merck
Alum = AL(OHPO4)SO, Al(OH)3, Al4(OHPO4)3; D = diphtheria; T = tetanus; aP = acellular Pertusis; wP = whole Pertusis; 
wL = Leptospira; IPV = inactivated poliovirus; IHA = inactivated hepatitis A; IJE = inactivated Japanese encephalitis; 
IR = inactivated rabies; Hib = Haemophylus influenzae b; HB = hepatitis B; L = Leptospira; PV = poliovirus; AFPL1™ 
= Finlay adjuvant proteoliposome 1; MPL = monophosphoryl lipid A; VLP = virus-like particle; im = intramuscular; sc = 
subcutaneous; NTM = no trademark.
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Table 4. Newly licensed adjuvants. 
Adjuvant IP DS IPz Vaccine Manufacturer
 1 Al(OH)3 I Influenza X Th2 Several See Table 3
 2 Al4(OHPO4)3 I Influenza X Th2 Several See Table 3
 3 AlOHPO4SO4 HPV X ? Gardasil™ Merck
 4 Ca3(PO4)2 DTP X Th2 Several Pasteur Institute
 5 MF59 I Influenza O/W Th2 Afluov™ (H5N3) Novartis
 Focetria™ (H5N1)
 6 MPL MPL - Th1 Allergy Allergy therapeutics
 7 AS03 I Influenza O/W ? Prepandrix™ (H5N1) GSK
 8 AS04 MPL Alum VLP Th1 Cervarix™ GSK
 9 RC529 MPL synthetic Alum Th1 Supervax™ Berna Biotech
10 Virosome (VLP, IRIV) IHA Lipid Th1 Epaxal™ Berna Biotech
11 Virosome (VLP, IRIV) I Influenza Lipid Th1 Inflexal™ V Berna Biotech
AFPL1™ Inserted LPS, porins, bacterial DNA Lipid Th1 CTL VA-MENGOC-BC™ Finlay
IP = immune potentiators; DS = delivery system; Ipz = immune polarizer; I = inactivated; Th = T helper lymphocyte; HPV = human 
papillomavirus; DTP = diphtheria, tetanus, pertussis; O/W = oil in water; MPL™ = monophosphoryl lipid A; AS03 = adjuvant system con-
taining a 10% oil-in-water emulsion-based adjuvant; AS04 = aqueous formulation of MPL and alum; alum = AL(OHPO4)SO, Al(OH)3, 
Al4(OHPO4)3; VLP = virus-like particle; IRIV = immunostimulating reconstituted influenza virosomes; HA = hepatitis A; AFPL1™ = Finlay 
adjuvant proteoliposome 1; LPS = lipopolysaccharide; CTL = cytotoxic T lymphocyte.
Table 5. Current issues in adjuvant research. 
 1 Adjuvants are considered by regulatory agencies as an integral part of the finished vaccine product. Consequently, adjuvants
are not licensed per se, including those that were used with co-administered antigens. 
 2 There is no international center for comparison of adjuvants and vaccine formulations. Consequently, we need to accept the
little and incomplete information available. In addition, potential adjuvant-antigen combinations have not been developed  
because of the high costs and efforts involved in gaining FDA or EMEA approval for each adjuvant-antigen combination. 
 3 A comprehensive overview, or comparative studies of adjuvants using model antigens and low and high immunogenic
antigens are not available.
 4 Lack of access to promising new adjuvants essential for new vaccines. Consequently, both big and small vaccine companies
focus on their own adjuvant research programs.
 5 Adjuvant development occurs mainly by big private vaccine companies, and therefore is bound to patent rights, and is not
available for commercialization. Consequently, they are not available to the public sector or small companies.
 6 Most vaccine companies keep their adjuvant formulations proprietary until the adjuvant is registered with a potential vaccine
product. Consequently, this limits the development of the adjuvant for other vaccine applications.
 7 New vaccines against life-threatening diseases (malaria, TB, and HIV) and neglected tropical diseases have been conducted
with non-optimized adjuvants. They either use alum (that induces only strong antibody responses) or water-in-oil emulsions,
which are the only freely available adjuvants.
 8 High costs are involved in developing novel adjuvants. Consequently, some otherwise viable antigens have been abandoned
as candidates for new vaccines due to lack of the correct adjuvant. This results in a significant waste of resources from
public and private sources.
 9 Lack of understanding that future vaccines need to be designed using alternative routes of immunization, particularly the
mucosal routes. Consequently, no mucosal adjuvant exists, and only a few promising ones have been studied.
10 Lack of realization that the polarization of the immune response is critical for induction of protection. Consequently, the
selection of the adjuvant continues to be empirical for some vaccines.
11 The challenge is to establish a system that provides open access to adjuvants and adjuvant information to non-profit and profit
initiatives, without impairing the freedom-of-operation of the adjuvant owner.
FDA = food and drug administration; EMEA = European medicines agency; TB = tuberculosis; HIV = human immunodeficiency virus.
